Navigation Links
Founder of National Children's Leukemia Unveiled Non-Embryonic Stem Cell Treatment Promising Cure for Cancer at GIL 2012: Europe

LONDON, May 9, 2012 /PRNewswire/ -- A monumental discovery that provides the promise of a cure not only for leukaemia, but cancer at large was announced this morning in London during GIL 2012: Europe. Steve Shor, the founder of the National Children's Leukemia Foundation, a leading non-profit organisation in the United States, unveiled a ground-breaking therapy his research teams in the United States and Israel have discovered. Mr. Shor and National Program Director, Dr. Sara Gardin, presented this new non-embryonic stem cell treatment for cancer and leukaemia, referred to as the "Stem cell cocktail" which delivers a combination of therapies including core stem cells and various compounds to tackle cell metastasization.

Just a few weeks ago, this unique approach to tackling one of the most prominent forms of cancer of our time received initial patent approval with full patents expected in the coming months.

Steve Shor delivered an emotional appeal and address that captured the undivided attention of some two hundred plus senior level business executives representing this global network of visionaries, innovators and leaders gathered in London for Frost & Sullivan's GIL 2012: Europe - Journey to Visionary Innovation. Mr. Shor, a construction business owner from Brooklyn, New York, who had given up his successful career in 1992 to search out a bone marrow donor, when he discovered that his 17-year old son had been diagnosed with leukaemia. His son unfortunately never received a bone marrow transplant and lost his fight with leukaemia. Steve has continued to dedicate his life to cancer research founding the National Children's Leukemia Foundation and working with scientists in hopes to find "The Cure."

"I always thought the cure for cancer had to come from core stem cells," Steve said. "We started from a very different point. We asked: what are the mechanisms that make cancer cells grow?"

First time trial left them sceptical but upon continuous trials with positive outcomes, the team at the NCLF research institute in Israel knew they have uncovered a ground breaking monumental discovery with not only finding promise in a cure and treatment for leukaemia, but all cancers as well.

"A cure not only for leukaemia but cancer at large is within reach. We will see a cure for cancer within our generation," concluded Mr. Shor.

Steve Shor was recognised for his visionary leadership in finding a cure for leukaemia by the Frost & Sullivan community of visionaries, innovators and leaders - GIL Global with the presentation of Frost & Sullivan's 2012 Growth, Innovation and Leadership Lifetime Achievement Award by Vice President & Global Head of GIL, Brian Denker.

"One year ago, I stood here in London and posed a question to our GIL Europe delegation -- What is a world without cancer? Today, a year later, I return back to this side of the Atlantic with a promise of hope by way of an individual who has successfully found visionary innovation in his own journey in the wake of tragedy and struggle." Denker concluded by asking each member of the GIL Global community to go forward, continually revisiting three profound questions we all must continue to ask ourselves. Firstly, what does it mean to truly innovate; second, what does it mean to inspire; and lastly, how can we ourselves bridge innovation and inspiration?

To interview Mr. Denker and Mr. Shor and to know more about Frost & Sullivan's journey to visionary innovation, please contact Chiara Carella, Corporate Communications, at

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents. To join our Growth Partnership, please visit

Chiara Carella
Corporate Communications - Europe
P: +44 (0) 20 7343 8314
M: +44 (0) 753 3017689




SOURCE Frost & Sullivan
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Radiotherapy Clinics of Georgias Founder Returns Home to Celebrate Cancer Survivors and Receive Lifetime Achievement Award
2. Telome Health Co-founder and Nobel Laureate Elizabeth Blackburn Awarded Innovator of the Year
3. Pandora Founder Tim Westergren and Co-Discoverer of DNA Dr. James Watson Meet
4. Founder of Cryonics Movement Dies, is Frozen at Cryonics Institute
5. Generex Announces U.S. Congressman Curt Weldon, Co-Founder of the Congressional Diabetes Caucus, to Champion Generex Initiatives in Asia and North America
6. Most Expensive Teas in the World Worth US$44,500 per 4 Ounces Each are Positioned for International Distribution Says Protein Reactor Combined Fuels Inc (OTC: PRCF) Founder Chairman and CEO Nestor C. Buenaflor
7. Glencoe Software and Open Microscopy Environment Founder Awarded the BBSRC Innovator of the Year 2011
8. HumanTouch Founder, President and CEO, Moe Jafari Named Washington Business Journal Minority Business Leader Honoree
9. Cord Blood America CEO and Co-Founder Matthew Schissler Named Chairman of Biotech Committee for Nevada Development Authority
10. Cephalon to Hold Public Memorial Service to Celebrate the Life of Company Founder, Frank Baldino, Jr., Ph.D.
11. Cephalon Mourns the Passing of Founder, Chairman and CEO, Frank Baldino Jr., Ph.D.
Post Your Comments:
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... SILVER SPRING, Md. , June 23, 2016 ... evidence collected from the crime scene to track the criminal ... sick, and the U.S. Food and Drug Administration (FDA) uses ... Sound far-fetched? It,s not. ... whole genome sequencing to support investigations of foodborne illnesses. Put ...
(Date:6/23/2016)... ... 2016 , ... Charm Sciences, Inc. is pleased to announce ... Research Institute approval 061601. , “This is another AOAC-RI approval of the Peel ... President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably to ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
Breaking Biology Technology:
(Date:4/19/2016)... 2016 The new GEZE SecuLogic ... web-based "all-in-one" system solution for all door components. It ... the door interface with integration authorization management system, and ... The minimal dimensions of the access control and the ... installations offer considerable freedom of design with regard to ...
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting Medicaid ... setting a new clinical standard in telehealth thanks to ... leveraging the higi platform, IMPOWER patients can routinely track ... and body mass index, and, when they opt in, ... convenient visit to a local retail location at no ...
(Date:3/23/2016)... , March 23, 2016 ... erhöhter Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender ... das Unternehmen mit SpeechPro zusammenarbeitet, um erstmals ... Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im Rahmen ...
Breaking Biology News(10 mins):